Published in Lancet Neurol on April 03, 2014
Autoimmune encephalopathies. Ann N Y Acad Sci (2014) 1.65
DPPX potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients. Neurology (2014) 1.21
Sleep disorder associated with antibodies to IgLON5: parasomnia or agrypnia? Lancet Neurol (2014) 1.12
Sleep disorder, chorea, and dementia associated with IgLON5 antibodies. Neurol Neuroimmunol Neuroinflamm (2015) 1.07
Antibody-Mediated Autoimmune Encephalopathies and Immunotherapies. Neurotherapeutics (2016) 1.02
Neuroimmunology: an expanding frontier in autoimmunity. Front Immunol (2015) 0.93
High prevalence of NMDA receptor IgA/IgM antibodies in different dementia types. Ann Clin Transl Neurol (2014) 0.93
Sleep disorder associated with antibodies to IgLON5: parasomnia or agrypnia?-Authors' reply. Lancet Neurol (2014) 0.92
Cellular investigations with human antibodies associated with the anti-IgLON5 syndrome. J Neuroinflammation (2016) 0.91
Neuropathological criteria of anti-IgLON5-related tauopathy. Acta Neuropathol (2016) 0.89
Friend or foe? IgLON5 antibodies in a novel tauopathy with prominent sleep movement disorder, ataxia, and chorea. Mov Disord (2014) 0.85
Autoimmune synaptopathies. Nat Rev Neurosci (2016) 0.82
Neuronal surface antibody-mediated autoimmune encephalitis. Semin Neurol (2014) 0.82
Detection and Characterization of Autoantibodies to Neuronal Cell-Surface Antigens in the Central Nervous System. Front Mol Neurosci (2016) 0.81
Isolated dysphagia as initial sign of anti-IgLON5 syndrome. Neurol Neuroimmunol Neuroinflamm (2016) 0.80
Clinical and experimental studies of potentially pathogenic brain-directed autoantibodies: current knowledge and future directions. J Neurol (2014) 0.78
Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System. Physiol Rev (2017) 0.78
Rapid Eye Movement Sleep Behavior Disorder in Paraneoplastic Cerebellar Degeneration: Improvement with Immunotherapy. Sleep (2016) 0.77
DPPX antibody-associated encephalitis: Main syndrome and antibody effects. Neurology (2017) 0.75
Neurochondrin is a neuronal target antigen in autoimmune cerebellar degeneration. Neurol Neuroimmunol Neuroinflamm (2016) 0.75
Netrin-1 receptor antibodies in thymoma-associated neuromyotonia with myasthenia gravis. Neurology (2017) 0.75
Brain Infiltration of Immune Cells in CASPR2-Antibody Associated Mesial Temporal Lobe Epilepsy with Hippocampal Sclerosis. Noro Psikiyatr Ars (2016) 0.75
Antibody-mediated central nervous system diseases: disease recognition and treatment challenges. Clin Exp Immunol (2014) 0.75
Paralysis lost: a new cause for a common parasomnia? Lancet Neurol (2014) 0.75
Promoter-Specific Expression and Genomic Structure of IgLON Family Genes in Mouse. Front Neurosci (2017) 0.75
Adaptive Immunity Is the Key to the Understanding of Autoimmune and Paraneoplastic Inflammatory Central Nervous System Disorders. Front Immunol (2017) 0.75
IgLON5 antibody: Neurological accompaniments and outcomes in 20 patients. Neurol Neuroimmunol Neuroinflamm (2017) 0.75
IgLON5 disease responsive to immunotherapy. Neurol Neuroimmunol Neuroinflamm (2017) 0.75
Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol (2008) 21.53
Reactivation of hippocampal ensemble memories during sleep. Science (1994) 11.04
Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology (1996) 8.82
Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. Brain (2005) 6.81
Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol (2009) 5.75
Sleep state switching. Neuron (2010) 4.94
Temporally structured replay of awake hippocampal ensemble activity during rapid eye movement sleep. Neuron (2001) 4.16
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Neuronal autoantigens--pathogenesis, associated disorders and antibody testing. Nat Rev Neurol (2012) 3.20
Morvan syndrome: clinical and serological observations in 29 cases. Ann Neurol (2012) 3.12
Electrophysiological comparison of pyramidal and stellate nonpyramidal neurons in dissociated cell culture of rat hippocampus. Brain Res Bull (1991) 2.69
Tau pathology and neurodegeneration. Lancet Neurol (2013) 2.66
Severe obstructive sleep apnea/hypopnea mimicking REM sleep behavior disorder. Sleep (2005) 2.39
Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. Lancet Neurol (2013) 2.30
The DNA sequence and biology of human chromosome 19. Nature (2004) 2.29
Sleep and reported daytime sleepiness in normal subjects: the Sleep Heart Health Study. Sleep (2004) 1.93
What is IgG4? A review of the biology of a unique immunoglobulin subtype. Curr Opin Rheumatol (2011) 1.85
Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease. Neurology (2003) 1.79
Sleep manifestations of voltage-gated potassium channel complex autoimmunity. Arch Neurol (2011) 1.77
Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. Eur J Neurol (2009) 1.76
The immunology of neurodegeneration. J Clin Invest (2012) 1.41
Rapid eye movement sleep behavior disorder and potassium channel antibody-associated limbic encephalitis. Ann Neurol (2006) 1.37
The neuronal network responsible for paradoxical sleep and its dysfunctions causing narcolepsy and rapid eye movement (REM) behavior disorder. Sleep Med Rev (2010) 1.33
Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med (2013) 1.31
A parasomnia overlap disorder involving sleepwalking, sleep terrors, and REM sleep behavior disorder in 33 polysomnographically confirmed cases. Sleep (1997) 1.21
Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. Brain (2012) 1.19
Status dissociatus--a perspective on states of being. Sleep (1991) 1.12
Axo-glial antigens as targets in multiple sclerosis: implications for axonal and grey matter injury. J Mol Med (Berl) (2010) 1.11
Agrypnia Excitata: a generalized overactivity syndrome and a useful concept in the neurophysiopathology of sleep. Clin Neurophysiol (2002) 1.11
Upper airway dysfunction of Tau-P301L mice correlates with tauopathy in midbrain and ponto-medullary brainstem nuclei. J Neurosci (2010) 1.08
Neural GPI-anchored cell adhesion molecules. Front Biosci (2003) 1.05
Pathogenic and physiological autoantibodies in the central nervous system. Immunol Rev (2012) 1.01
IgLON cell adhesion molecule Kilon is a crucial modulator for synapse number in hippocampal neurons. Brain Res (2008) 1.01
Stages 1-2 non-rapid eye movement sleep behavior disorder associated with dementia: a new parasomnia? Mov Disord (2005) 0.92
Scoring sleep in neurological patients: the need for specific considerations. Sleep (2011) 0.91
Isolated bulbar paralysis in a patient with medullar tau pathology: a case report. J Neurol Neurosurg Psychiatry (2010) 0.90
[Esophageal achalasia, sleep disorders and chorea in a tauopathy without ophthalmoplegia, parkinsonian syndrome, nor dementia (progressive supranuclear palsy?): clinicopathological study]. Rev Neurol (Paris) (2008) 0.89
Phenotypic variability within the inclusion body spectrum of basophilic inclusion body disease and neuronal intermediate filament inclusion disease in frontotemporal lobar degenerations with FUS-positive inclusions. J Neuropathol Exp Neurol (2012) 0.87
Allelic and haplotypic HLA frequency distribution in Spanish hematopoietic patients. Implications for unrelated donor searching. Tissue Antigens (2011) 0.85
Sleep disorder associated with antibodies to IgLON5: parasomnia or agrypnia?-Authors' reply. Lancet Neurol (2014) 0.92
Zonisamide attenuates lactacystin-induced parkinsonism in mice without affecting system xc. Exp Neurol (2016) 0.76